机构持仓方面，截止2025年9月30日，亚辉龙十大流通股东中，华宝中证医疗ETF（512170）位居第七 大流通股东，持股965.16万股，相比上期减少176.69万股。 责任编辑：小浪快报 截至9月30日，亚辉龙股东户数1.28万，较上期增加7.40%；人均流通股44595股，较上期减少6.89%。 2025年1月-9月，亚辉龙实现营业收入12.87亿元，同比减少7.69%；归母净利润6042.09万元，同比减少 72.36%。 分红方面，亚辉龙A股上市后累计派现6.93亿元。近三年，累计派现5.31亿元。 11月21日，亚辉龙跌3.68%，成交额9994.92万元。两融数据显示，当日亚辉龙获融资买入额1253.69万 元，融资偿还1579.12万元，融资净买入-325.43万元。截至11月21日，亚辉龙融资融券余额合计4.45亿 元。 融资方面，亚辉龙当日融资买入1253.69万元。当前融资余额4.43亿元，占流通市值的5.21%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，亚辉龙11月21日融券偿还0.00股，融券卖出400.00股，按当日收盘价计算，卖出金额5964.00 元；融券余量 ...

Group 1 - The core point of the news is that Aihuilong's stock price increased by 5.21% to 16.15 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.77%, resulting in a total market capitalization of 9.212 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay methods [1] - The company's revenue composition includes self-produced reagents (non-COVID products) at 58.57%, self-produced consumables (non-COVID products) at 12.60%, self-produced instruments (non-COVID products) at 11.92%, and various agency sales [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund holds a significant position, having reduced its holdings by 1.7669 million shares in the third quarter, now owning 9.6516 million shares, which is 1.69% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) has a total scale of 26.404 billion CNY and has achieved a year-to-date return of 11.75% [2] - The fund manager, Hu Jie, has a tenure of 13 years and 31 days, with the fund's total asset scale reaching 100.204 billion CNY [3]

Group 1 - The core viewpoint of the news is that Aihuilong's stock price increased by 5.27%, reaching 15.39 CNY per share, with a total market capitalization of 8.779 billion CNY as of the report date [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescent immunoassay methods [1] - The company's revenue composition includes 58.57% from self-produced reagents (non-COVID products), 12.60% from self-produced consumables (non-COVID products), and 11.92% from self-produced instruments (non-COVID products) [1] Group 2 - Huabao Zhongzheng Medical ETF (512170) is among the top ten circulating shareholders of Aihuilong, having increased its holdings by 171,400 shares in the second quarter, now holding 11.4185 million shares, which is 2% of the circulating shares [2] - The fund has achieved a year-to-date return of 14.75% and a one-year return of 6.63%, ranking 3345 out of 4218 and 3530 out of 3878 in its category, respectively [2]

Core Viewpoint - The company, Aihuilong, experienced a decline in stock price and trading volume, with significant financing activities indicating high leverage levels in the market [1][2]. Group 1: Financial Performance - For the first half of 2025, Aihuilong reported revenue of 808 million yuan, a year-on-year decrease of 15.79% [2]. - The net profit attributable to shareholders was 26.27 million yuan, reflecting a substantial year-on-year decline of 84.82% [2]. Group 2: Shareholder and Market Activity - As of August 26, Aihuilong's financing balance was 455 million yuan, accounting for 5.01% of its market capitalization, indicating a high level of leverage compared to the past year [1]. - The company had a total of 11,900 shareholders as of June 30, with a decrease of 4.07% from the previous period [2]. - The average number of circulating shares per shareholder increased by 4.27% to 47,894 shares [2]. Group 3: Dividend and Institutional Holdings - Aihuilong has distributed a total of 693 million yuan in dividends since its A-share listing, with 531 million yuan distributed over the past three years [3]. - As of June 30, 2025, Huabao Zhongzheng Medical ETF was the sixth largest circulating shareholder, holding 11.42 million shares, an increase of 171,400 shares from the previous period [3].